Evidence map›Paper›PMID 37358671›Full record

SynthesisEuropean journal of epidemiology2023

Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19.

Shiqi Lin, Xingjian Gao, Frauke Degenhardt, Yu Qian, Tianzi Liu, Xavier Farre Ramon, Syed Sibte Hadi, Manuel Romero-Gómez, Javier Fernández, Agustín Albillos and 7 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 6 countries.

Shiqi Lin *CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0001-9518-2027
Xingjian Gao *CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0002-6142-8102
Frauke Degenhardt *Institute of Clinical Molecular Biology and University Hospital of Schleswig-Holstein, Christian-Albrechts-University, Rosalind-Franklin-Str. 12, 24105, Kiel, Germany.ORCID http://orcid.org/0000-0001-7516-3179
Yu QianCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0003-1327-9891
Tianzi LiuCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.ORCID http://orcid.org/0000-0002-7401-3571
Xavier Farre RamonGenomes for Life-GCAT Lab., Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.ORCID http://orcid.org/0000-0001-6838-9479
Syed Sibte HadiDepartment of Forensic Sciences, College of Criminal Justice, Naif Arab University of Security Sciences, 11452, Riyadh, Kingdom of Saudi Arabia.ORCID http://orcid.org/0000-0002-2994-3083
Manuel Romero-GómezCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0001-8494-8947
Javier FernándezHospital Clinic, University of Barcelona, and IDIBAPS, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5622-0489
Agustín AlbillosCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0001-9131-2592
Maria Buti FerretCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-0732-3078
Luis BujandaCentro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-4353-9968
Antonio JuliàVall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6064-3620
Rafael de CidDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.ORCID http://orcid.org/0000-0003-3579-6777
Rosanna AsseltaDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy. rosanna.asselta@hunimed.eu.ORCID http://orcid.org/0000-0001-5351-0619
Andre FrankeInstitute of Clinical Molecular Biology and University Hospital of Schleswig-Holstein, Christian-Albrechts-University, Rosalind-Franklin-Str. 12, 24105, Kiel, Germany.ORCID http://orcid.org/0000-0003-1530-5811
Fan LiuCAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China. fliu@nauss.edu.sa.ORCID http://orcid.org/0000-0001-9241-8161
Chinese Academy of Sciences · CNChristian-Albrechts-Universität zu Kiel · DEHumanitas University · ITBeijing Institute of Genomics · CNEuropean Foundation for the Study of Chronic Liver Failure · ESIkerbasque · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESInstituto de Salud Carlos III · ESNaif Arab University for Security Sciences · SAUniversidad de Alcalá · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

Naif Arab University for Security Sciences PR2-10National Natural Science Foundation of China 81930056Science and Technology Service Network Initiative of Chinese Academy of Sciences KFJ-STS-QYZD-2021-08-001Science and Technology Service Network Initiative of Chinese Academy of Sciences KFJ-STS-ZDTP-079Shanghai Municipal Science and Technology Major Project 2017SHZDZX01Strategic Priority Research Program of Chinese Academy of Sciences XDB38010400Strategic Priority Research Program of Chinese Academy of Sciences XDC01000000
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to life-threatening respiratory symptoms. Understanding the genetic basis of the prognosis of COVID-19 is important for risk profiling of potentially severe symptoms. Here, we conducted a genome-wide epistasis study of COVID-19 severity in 2243 patients with severe symptoms and 12,612 patients with no or mild symptoms from the UK Biobank, followed by a replication study in an independent Spanish cohort (1416 cases, 4382 controls). Our study highlighted 3 interactions with genome-wide significance in the discovery phase, nominally significant in the replication phase, and enhanced significance in the meta-analysis. For example, the lead interaction was found between rs9792388 upstream of PDGFRL and rs3025892 downstream of SNAP25, where the composite genotype of rs3025892 CT and rs9792388 CA/AA showed higher risk of severe disease than any other genotypes (P = 2.77 × 10

Indexed as

COVID-19Epistasis, GeneticGenotypeHumansSARS-CoV-2COVID-19EpistasisGene–gene interactionGenome-wide association studySeverityUK Biobank

Identifiers

PMID37358671
OpenAlexW4382011319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.